MetLife Investment Management’s Prothena Corp PRTA Stock Holding History

MetLife Investment Management’s Portfolio PRTA Stock Details PRTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$253K	Buy	25,890 +6,374	+33%	+$62.9K	﹤0.01%	2297
2026 Q1	$190K	Sell	19,516 -5,985	-23%	-$54.8K	﹤0.01%	2259
2025 Q4	$244K	Buy	25,501 +6,139	+32%	+$62.5K	﹤0.01%	2182
2025 Q3	$189K	Sell	19,362 -6,040	-24%	-$46.4K	﹤0.01%	2352
2025 Q2	$154K	Hold	25,402	–	–	﹤0.01%	2319
2025 Q1	$314K	Sell	25,402 -471	-2%	-$6.66K	﹤0.01%	1947
2024 Q4	$358K	Buy	25,873 +536	+2%	+$8.46K	﹤0.01%	1980
2024 Q3	$424K	Hold	25,337	–	–	﹤0.01%	1868
2024 Q2	$523K	Buy	25,337 +3,485	+16%	+$75.4K	﹤0.01%	1697
2024 Q1	$541K	Hold	21,852	–	–	﹤0.01%	1631
2023 Q4	$794K	Hold	21,852	–	–	0.01%	1429
2023 Q3	$1.05M	Hold	21,852	–	–	0.01%	1199
2023 Q2	$1.49M	Buy	21,852 +1,302	+6%	+$84K	0.01%	1061
2023 Q1	$996K	Buy	20,550 +989	+5%	+$52.2K	0.01%	1225
2022 Q4	$1.18M	Hold	19,561	–	–	0.01%	1137
2022 Q3	$1.19M	Hold	19,561	–	–	0.01%	1106
2022 Q2	$531K	Hold	19,561	–	–	﹤0.01%	1610
2022 Q1	$715K	Buy	19,561 +6,951	+55%	+$251K	﹤0.01%	1546
2021 Q4	$623K	Hold	12,610	–	–	0.01%	1390
2021 Q3	$898K	Hold	12,610	–	–	0.01%	1174
2021 Q2	$648K	Hold	12,610	–	–	0.01%	1422
2021 Q1	$317K	Sell	12,610 -5,714	-31%	-$108K	﹤0.01%	1785
2020 Q4	$220K	Hold	18,324	–	–	﹤0.01%	1930
2020 Q3	$183K	Hold	18,324	–	–	﹤0.01%	1911
2020 Q2	$192K	Hold	18,324	–	–	﹤0.01%	1934
2020 Q1	$196K	Hold	18,324	–	–	﹤0.01%	1707
2019 Q4	$290K	Hold	18,324	–	–	﹤0.01%	1773
2019 Q3	$144K	Hold	18,324	–	–	﹤0.01%	2132
2019 Q2	$194K	Hold	18,324	–	–	﹤0.01%	2040
2019 Q1	$222K	Hold	18,324	–	–	﹤0.01%	2312
2018 Q4	$189K	Hold	18,324	–	–	﹤0.01%	1940
2018 Q3	$240K	Buy	+18,324	New	+$265K	﹤0.01%	1981

Other funds holding PRTA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

MetLife Investment Management's PRTA Position: Q2 2026 in Review

MetLife Investment Management increased its Prothena Corp (PRTA) stake by 33% in Q2 2026, buying an estimated $62.9K and bringing the position to 25,890 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #2297.

MetLife Investment Management first reported a position in PRTA in Q3 2018 and has held it in 32 quarters since. The position peaked at $1.49M in Q2 2023. 187 funds tracked by Wall St. Rank hold PRTA as of Q2 2026.

MetLife Investment Management held 25,890 shares of Prothena Corp worth $253K as of Q2 2026.
MetLife Investment Management bought 6,374 Prothena Corp shares in Q2 2026, an estimated $62.9K.
Prothena Corp made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2297 holding.
MetLife Investment Management first reported a position in Prothena Corp in Q3 2018 and has held it in 32 quarters since.
MetLife Investment Management's Prothena Corp position peaked at $1.49M in Q2 2023.
187 funds tracked by Wall St. Rank held Prothena Corp as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.